Skip to main content

Table 1 Possible radiotherapy protocols for treatment of patients with LASCCHN according to Bonner et al. (12), plus modification for IMRT

From: Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (Head and neck cancer: ImmunoChemo and Radiotherapy with Erbitux) – a multicenter phase IV trial

Regime

Total dose

Single dose (once a day)

Single dose (twice a day)

Once a day

70 Gy in 35 fractions

2 Gy/fraction; 5fractions/weekduration: 7 weeks

--

Twice a day

72-76,8 Gy in 60–64 fractions

--

1,2 Gy/fraction; 10 fractions/week Duration: 6–6,5 weeks

Concomitant boost

72 Gy in 42 fractions

32,4 Gy; 1,8 Gy/fraction; 5 fractions/week duration: 3,6 weeks

a.m.: 21,6 Gy; 1,8 Gy/fraction; 5 fractions/week Duration: 2,4 weeks p.m.: 18 Gy; 1,5 Gy/fraction; 5 fractions/week Duration: 2,4 weeks

(helical) IMRT

66 Gy in 30 fractions

Intergrated Boost 5 fractions /week duration: 6 weeks

--